Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy
Aoe, K.; Hiraki, A.; Murakami, T.; Maeda, T.; Umemori, Y.; Katayama, H.; Eda, R.; Takeyama, H.
Anticancer Research 25(1b): 415-418
2005
ISSN/ISBN: 0250-7005 PMID: 15816604 Document Number: 588815
Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase which is effective for patients with advanced non-small cell lung cancer. A 75-year-old man with advanced adenocarcinoma of the lung was treated with gefitinib. He had a history of allergy to several antibiotics and Welder's lung. Two days after initiation, he developed acute interstitial lung disease (ILD) and died of respiratory failure due to progression of ILD. Critical assessment pointed to gefitinib as the likely cause of this complication. This is the first report of rapid gefitinib-induced ILD. This case should alert physicians to the potential for dangerous pulmonary side-effects of gefitinib therapy, especially in patients with drug allergy.